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Old age, male gender, poor medical compliance, hospitalization
and coexistent anti-platelet agents were the other signiﬁcant risk
factors of developing stroke in these uncomplicated hypertensive
patients treated with various antihypertensive agents.
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OBJECTIVES: To compare efﬁcacy of rosuvastatin (RSV) and
ezetimibe/simvastatin (E/S) to take dyslipidemic patients to their
LDL-C goals according to ATPIII guidelines in the cardiology
clinical practice. Secondary objective was to compare the efﬁcacy
of both treatments to change lipids levels (LDL-C, TC, TG,
HDL-C ApoB/ApoA1 index) from baseline to week 8.
METHODS: Files from dyslipidemic outpatients in the Cardiol-
ogy Unit of a 3rd level hospital in Mexico City were reviewed
between Jan 2004–Dec 2005. Patients treated with either RSV
10 mg/day or E/S 10/20 mg/day and lipid determinations before
(basal) and after 8 weeks of treatment were included. Regression
models were used to adjust outcome measures for age, sex, CHD,
baseline LDL-C, and therapy duration. To assess the primary
objective, patients were classiﬁed as achieving lipid goals or not
according to ATPIII. Statistic analysis was made with a propor-
tion test. For secondary objectives, mean percent lipid change
(MPLC) achieved by each treatment were noted and differences
detected by Student’s t test with a p < 0.05 for signiﬁcance.
RESULTS: Files from 98 (age 63.1 ± 12.4 years) patients treated
with RSV and 89 (age 65.8 ± 12.8 years) treated with E/S were
reviewed. There were no signiﬁcant differences between groups
at baseline. A total of 81.4% and 46.4% RSV patients achieved
the 2001 and 2004 lipid ATPIII goals respectively, versus 58.4%
and 31.5% E/S patients (p < 0.01). The MPLC were: LDL-C:
RSV −46.7 ± 13.6 versus E/S −35 ± 21.3 (p < 0.001); TC: RSV
−33.6 ± 12.7 versus E/S −25.8 ± 16.7 (p < 0.001); HDL-C: RSV
9.9 ± 16.9 versus E/S 4.17 ± 16.5 (p = 0.012) ApoB/ApoA1
index: RSV −21 ± 29 versus E/S −10.7 ± 20 (p = 0.019). There
were no reports of adverse events with any treatment. CON-
CLUSION: More RSV patients achieved their LDL-C goals than
E/S patients. RSV treatment reduced more LDL-C, TC and
apoB/apoA1 index (atherogenic lipid proﬁle) and higher HDL-
C levels than E/S in the usual clinical practice in Mexican
patients.
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OBJECTIVES: We performed a meta-analysis to determine the
overall effectiveness of statins among hypertensive and non-
hypertensive patients. METHODS: We systematically reviewed
Medline publications from 1985 onwards for placebo-controlled
randomized trials that examined the effect of statins on cardiac
morbidity and mortality. Only trials that followed at least 1000
patients for two or more years were included in the meta-analy-
sis. Outcomes of interest included cardiac or cardiovascular
death, major coronary events, or major cardiovascular events.
Pooled estimates of relative risk were calculated separately for
(i) trials that prospectively randomized hypertensive patients to
statin therapy (ASCOT-LLA & ALLHAT-LLT); (ii) trials that
provided post-hoc cardiac event rates for subgroups of hyper-
tensive patients and non-hypertensive patients; (iii) trials that
provided only the baseline percentage of hypertension in the trial
population; and (iv) trials in (ii) and (iii) combined. The moder-
ating effect of the percentage of hypertensive patients at baseline
on the effectiveness of statins was tested using meta-regression.
RESULTS: Besides the ASCOT-LLA and ALLHAT-LLT, 12 trials
enrolling a total of 69,984 patients met the inclusion criteria.
Overall, in these 12 trials, statin therapy reduced cardiac death
by 24% (relative risk [RR]: 0.76; 95% conﬁdence interval [CI]:
0.71–0.82). Pooled relative risk for cardiac morbidity and mor-
tality was similar for trials in groups i, ii, iii, and iv and ranged
from 0.73–0.78. Relative risk estimates for hypertensive patients
(RR: 0.78; 95% CI: 0.72–0.84) and non-hypertensive (RR: 0.76;
95% CI: 0.72–0.80) subgroups were also similar. Consistent
with the subgroup analysis, the meta-regression showed that the
effect of statins on cardiac morbidity and mortality was not mod-
erated by the percentage of hypertensive patients at baseline (Q
estimate = 1.48; P = 0.22). CONCLUSION: Statin therapy effec-
tively reduces CV morbidity and mortality in both hypertensive
and non-hypertensive patients.
PCV4
CUMULATIVE PERSISTENCE OF ANTIHYPERTENSIVE
MEDICATION AS A NEWLY PRESCRIBED DRUG IN A
MEDICAID POPULATION
Gu A1, Shaya FT1,Weir MR2
1University of Maryland School of Pharmacy, Baltimore, MD, USA,
2University of Maryland, Baltimore, MD, USA
OBJECTIVES: To compare two-year persistence rates associated
with categories of antihypertensive medications among patients
who were newly prescribed antihypertensive medications in a
Medicaid Population. METHODS: The study is composed of all
continuously enrolled Maryland Medicaid patients aged 18 years
or older, with at least one prescription for selected antihyper-
tensive agents between 7/1/02 and 12/31/02, and no such pre-
scriptions in the preceding 6 months. Patients were followed for
two years since their index date. Selected antihypertensive agents
include angiotensin-converting enzyme inhibitors (ACEI),
angiotensin II antagonists (AIIA), beta-blockers (BB), calcium
channel blockers (CCB), diuretics, and ﬁxed-dose combinations.
Medication Possession Ratio (MPR) was assessed at 120, 240,
360, 480, 600 and 720 days after index date. Persistent was
deﬁned as MPR >= 80%. We used logistic regression and gener-
alized estimating equation (GEE) approaches to compare persis-
tent rates for each drug class at 720 days and over two years,
respectively. RESULTS: A total of 2967 patients qualiﬁed for
inclusion in the study. Persistence rates in the whole study sample
at 120, 240, 360, 480, 600 and 720 days were 41.6%, 29.9%,
22.4%, 17.7%, 14.4% and 11.1%, respectively. ACEIs were
associated with signiﬁcantly higher two-year persistence rates
than other classes, followed by CCBs. For the GEE model, over
two years, persistence rates among patients treated with ACEIs
were signiﬁcantly higher than patients treated with diuretics,
BBs, CCBs, and mixed dose combination therapy. ACEIs were
also associated with a slightly higher yet non-signiﬁcant persis-
tence rate than AIIAs. There were no signiﬁcant differences in
persistence rates among other classes. CONCLUSION: In this
Medicaid population, the antihypertensive medication persis-
tence rates among patients who were new users were critically
low. Persistence rates for ACEI are higher than those for CCBs,
BBs, AIIAs, diuretics and ﬁxed dose combinations.
